legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Siloton Secures Funding to Revolutionize Eye Imaging Technology

Introduction to Siloton’s Innovations

Siloton, a promising health technology start-up based in Bristol, has successfully secured £860,000 in funding aimed at advancing its commercial rollout of revolutionary eye imaging chip technology. This technology holds significant potential in addressing one of the UK’s most prevalent causes of sight loss, particularly among older adults and individuals with pre-existing conditions.

Funding Details and Future Development

The latest funding package is strategically designed to facilitate Siloton’s ongoing development of its Akepa optical coherence tomography (OCT) chip technology. The company is ambitiously working towards bringing a workable version of this advanced device to the market for researchers by the year 2025. Notably, later this year, Siloton strives to achieve a pioneering feat by capturing the very first chip-based OCT image of a living eye, within a commercial environment. This milestone is pivotal as it lays the groundwork for future clinical applications.

Support for this funding round has come from various sources, including the Evenlode Foundation, members of Southeast Angels, the prestigious Francis Crick Institute, and experienced angel investors. Moreover, the company has benefitted from non-dilutive funding through an Innovate UK Biomedical Catalyst grant, resulting in a total funding accumulated by Siloton to date reaching an impressive £1.7 million.

Addressing Sight Loss with Advanced Technology

Siloton’s cutting-edge technology is designed to enhance the diagnosis and monitoring of a spectrum of treatable retinal diseases. The key advantage of their technology lies in its ability to condense what would traditionally require a large, complex setup of expensive and fragile equipment into a compact chip that is smaller than a £1 coin. This innovation is not just a technological breakthrough but has the potential to reshape healthcare delivery. Estimates suggest that Siloton’s technology could lead to cost savings of over £1 billion annually for the NHS. Additionally, it empowers patients by enabling them to monitor their conditions from the comfort of their homes, reducing the need for frequent hospital visits.

Retinal diseases such as wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, which affect millions globally, can lead to severe vision impairment. In the UK alone, AMD accounts for the majority of sight loss cases, with approximately 39,800 new cases reported each year, as highlighted by the Macular Society.

Executive Insight on the Project’s Significance

Dr. Alasdair Price, CEO of Siloton, expressed confidence in the team’s ability to drive forward technology development at an unprecedented pace. He stated, "This new support will help us take the next step toward commercialisation, shifting from research and development to product development. The growing population affected by retinal diseases necessitates affordable and accessible OCT systems like our Akepa technology to serve patients with precision and efficiency. This innovation can potentially reduce preventable blindness and save healthcare providers billions while alleviating the strain on existing eye clinics."

Commitment to Transform Eye Healthcare

About Siloton

Siloton remains steadfast in its mission to provide life-saving eye scans to individuals suffering from eye diseases, ensuring access to necessary imaging services regardless of geographical location. Their groundbreaking photonic chip technology aims to elevate clinical-grade medical imaging systems to innovative devices that can operate anywhere. The company enjoys support from notable figures within the ophthalmology sector, including Moorfields Eye Hospital and the Macular Society itself. Additionally, Siloton’s customer base includes the European Space Agency, which is exploring long-term solutions for monitoring eye problems commonly faced by astronauts during space missions.

In July 2024, Siloton successfully completed its second round of investment, bolstering its funding to approximately £860,000. This financial injection is not only targeted at further developing the imaging setup needed for capturing the first live eye image but also at enhancing ongoing revenue-generating operations and securing ISO13485 accreditation.

To learn more about Siloton and its pioneering efforts, please visit Siloton’s website or follow updates on their LinkedIn page.

About Akepa: The Future of Optical Imaging

Akepa, the first-generation OCT chip developed by Siloton, integrates over 300 optical and electronic elements, marking a significant technological achievement. With about 70% of the OCT system already integrated directly onto the chip, it represents a level of sophistication that aligns closely with the requirements expected in the final product. Fabricated in a commercial foundry, Akepa also offers a clear path to high-volume manufacturing, which is vital for the widespread monitoring and treatment of retinal diseases.

Navigating legal Complexities with AI legalese decoder

In the rapidly evolving field of healthcare technology, navigating the legal landscape can become overwhelming for startups like Siloton. Here, AI legalese decoder can be an invaluable resource. This innovative tool can help decode complex legal language and contracts, enabling Siloton to better understand funding agreements, compliance requirements, and regulatory issues. By simplifying legal jargon, AI legalese decoder allows the team at Siloton to focus on what they do best: advancing life-changing technology for eye care without getting bogged down by legal uncertainties.

legalese decoder” />

In conclusion, Siloton’s advancements in eye imaging technology represent a significant leap forward in combating preventable sight loss, promising not only to improve patient outcomes but also to streamline healthcare costs and accessibility.

legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Reference link